Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 non-targeted AttIL-2
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PD-1 non-targeted AttIL-2 is an experimental antibody-cytokine fusion protein designed as a research control for TEV-56278. It consists of an attenuated form of interleukin-2 (AttIL-2) but lacks the PD-1-specific binding domain. In preclinical studies using patient-derived tumor fragments (PDTF) from renal cell carcinoma patients, it is used to differentiate the effects of systemic IL-2 receptor activation from the targeted, localized activation achieved by PD-1-directed delivery. The attenuated IL-2 moiety is engineered to have reduced affinity for IL-2 receptors compared to wild-type IL-2 (aldesleukin), aiming to expand the therapeutic window by reducing systemic toxicity while maintaining anti-tumor activity when properly targeted.
- Other names
- control PD-1 non-targeted-AttIL-2
02
Targets
IL2RB (IL-2 receptor beta chain)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on PD-1 non-targeted AttIL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 non-targeted AttIL-2.